{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"Scored according to the National Cancer Institute criteria. Mild-to-severe chronic GVHD at 2 years.","groups":[{"description":"Conditioning: Fludarabine IV over 30-60 minutes daily on days -6 through -2 and cyclophosphamide IV over 1-2 hours on days -6, -5, and 3-4. Patients undergo total-body irradiation on day -1.\n\nCell product: Patients undergo donor peripheral blood stem cell transplant on day 0.\n\nGVHD Prophylaxis: Patients then receive tacrolimus IV once daily or PO BID on days 5-180 (may be continued if active GvHD is present), mycophenolate mofetil IV or PO TID on days 5-35 (may be continued if GvHD present), and filgrastim IV beginning on day 5 until the ANC is \\>= 1,000/mm\\^3 for three consecutive days.","id":"OG000","title":"Treatment (Nonmyeloablative HCT, TBI)"}],"paramType":"NUMBER","populationDescription":"Patients who were alive greater than day 100 were included","reportingStatus":"POSTED","timeFrame":"Up to 2 years post-transplant","title":"Percentage of Participants With Chronic Graft Versus Host Disease","type":"PRIMARY","unitOfMeasure":"percentage of participants"}